Myocardial imaging radiopharmaceutical agents

Deutsch E, Elder RC, Laarge BA et al (1978) Structural characterization of a bridged technetium-99-tin-dimethylglyoxime complex implication for the technetium-99m-labeled radiopharmaceuticals prepared by tin(II) reduction of pertechnetate. Proc Natl Acad Sci USA 73 653-660 Deutsch E, Glavan KA, Sodd VJ et al (1981) Cationic Tc-99m complexes as potential myocardial imaging agents. J Nucl Med 22 897-907... 

Pasqualini R. Duatti A, Bellande E, Comazzi V, Brucato V et al (1994) Bis(dithiocarbamato)nitrido technetium-99m radiopharmaceuticals. A class of neutral myocardial imaging agents. J Nucl Med 35 334-341... 

Technetium ( Tc) radiopharmaceuticals such as (12.126) function as good myocardial imaging agents. Iron complexes of phosphorylated mono- and disaccharides will function as contrast agents in the MRI of the gastrointestinal tract [13]. 

Here we will recall just two of the advances made in the field of radiopharmaceuticals over the last few years. One shining example of an organometallic pharmaceutical that has been successfully commercialized is technetium-99m sestamibi, a hexakis (aUcyhsocyanide) complex of Tc(I) 29 that has become the most important myocardial imaging agent. The success of this compound, known by its trade name Cardiohte , has inspired researchers to develop other Tc-based radiopharmaceuticals [193-197]. 

---